HC Wainwright reaffirmed their buy rating on shares of Caribou Biosciences (NASDAQ:CRBU – Free Report) in a research report report published on Tuesday morning, Benzinga reports. They currently have a $9.00 price target on the stock.
A number of other research analysts have also recently issued reports on CRBU. Evercore ISI cut Caribou Biosciences from an outperform rating to an inline rating and decreased their target price for the company from $13.00 to $3.00 in a research note on Monday, June 3rd. Royal Bank of Canada restated an outperform rating and set a $14.00 target price on shares of Caribou Biosciences in a report on Wednesday, August 7th. Finally, Truist Financial reiterated a buy rating and issued a $19.00 price target on shares of Caribou Biosciences in a report on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Caribou Biosciences currently has a consensus rating of Moderate Buy and an average price target of $11.25.
View Our Latest Research Report on Caribou Biosciences
Caribou Biosciences Price Performance
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. The company had revenue of $3.46 million for the quarter, compared to analyst estimates of $3.31 million. Equities research analysts expect that Caribou Biosciences will post -1.76 earnings per share for the current year.
Hedge Funds Weigh In On Caribou Biosciences
Large investors have recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in shares of Caribou Biosciences in the second quarter worth $2,432,000. Dimensional Fund Advisors LP grew its holdings in shares of Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock valued at $4,302,000 after acquiring an additional 536,162 shares in the last quarter. Avidity Partners Management LP raised its holdings in Caribou Biosciences by 5.1% during the fourth quarter. Avidity Partners Management LP now owns 6,360,212 shares of the company’s stock worth $36,444,000 after acquiring an additional 310,000 shares in the last quarter. XTX Topco Ltd bought a new stake in Caribou Biosciences during the second quarter worth about $341,000. Finally, Vanguard Group Inc. grew its stake in Caribou Biosciences by 3.8% in the first quarter. Vanguard Group Inc. now owns 4,110,795 shares of the company’s stock valued at $21,129,000 after purchasing an additional 148,751 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.
Featured Articles
- Five stocks we like better than Caribou Biosciences
- 3 REITs to Buy and Hold for the Long Term
- Emerging Markets: What They Are and Why They Matter
- What is Insider Trading? What You Can Learn from Insider Trading
- Recession or Not, These 3 Stocks Are Winners
- Business Services Stocks Investing
- Why NVIDIA Is More of a Screaming Buy Than Ever
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.